Intestinal transcriptomic analysis and prediction of biomarkers associated with mucosal healing following vedolizumab treatment in ulcerative colitis using machine learning

Read full text
Authors: Katsuyoshi Ando, Shin Kashima, Aki Sakatani, Hiroaki Konishi, Atsuo Maemoto, Takahiro Ito, Masaki Taruishi, Kaori Ishiguro, Mikihiro Fujiya
Cited by: 1
References: 39

Abstract

BACKGROUND: There is an increasing need for predictors of clinical outcomes in patients with ulcerative colitis (UC). In this exploratory analysis, we aimed to analyze the gene expression profile of intestinal tissues according to treatment outcome in patients with UC treated with vedolizumab and to develop a treatment outcome prediction model. METHODS: Transcriptomic analysis of intestinal tissues at the inflammation site (week 0) of patients (N = 10), stratified by mucosal healing status at week 54 after vedolizumab 300 mg treatment, was performed to identify differentially expressed genes (DEGs) with ≥ 1.5-fold difference and P < 0.05. Vedolizumab-related ‘hub’ genes were identified by network analysis (cytoHubba). Candidate biomarkers were selected and a prediction model for mucosal healing was developed using the least absolute shrinkage and selection operator (LASSO) algorithm (a machine learning method that helps to identify the most relevant genes for prediction while avoiding overfitting), which was validated with a public dataset (GSE73661). RESULTS: Transcriptomic analysis revealed 375 DEGs associated with vedolizumab mucosal healing. Gene enrichment analysis revealed terms associated with T cell activation and immune regulation. Eighteen hub genes were identified. A prediction model developed and validated with a public dataset had AUC–ROC values of 0.800 (95% CI, 0.551–1.000) and 0.750 (95% CI, 0.350–1.000) for the week 12 and 52 vedolizumab validation cohorts, respectively. In contrast, the AUC–ROC was 0.575 (95% CI, 0.317–0.833) for the week 4–6 infliximab validation cohort, suggesting that the model is specific for vedolizumab-associated clinical outcomes. CONCLUSIONS: We identified hub genes that were related to vedolizumab treatment outcomes. A prediction model of vedolizumab-associated mucosal healing was developed and validated with a public dataset.

Fields of Study & Subjects

Inflammatory Bowel Disease Ferroptosis and cancer prognosis Gut microbiota and health

Publication details

Journal / source
BMC Gastroenterology
Publisher
Springer Science and Business Media LLC
Volume
26
Issue
1
Pages
117–117
Publication date
17 January 2026
Language
EN